Announcement PDF Appendix 3Z Final Director’s Interest Notice Appendix 3Z Rule 3.19A.3 Final Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/9/2001. Name of entity Neuren Pharmaceuticals Limited ABN 72 111 496 130 We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of director Trevor Scott Date of last notice 14 June 2023 Date that director ceased to be director 30 June 2024 Part 1 – Director’s relevant interests in securities of which the director is the registered holder In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Number & class of securities + See chapter 19 for defined terms. 11/3/2002 Appendix 3Z Page 1 Appendix 3Z Final Director’s Interest Notice Part 2 – Director’s relevant interests in securities of which the director is not the registered holder Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Name of holder & nature of interest Number & class of securities Beneficiary of Ordinary Shares under registered holders Essex Castle Limited and Centralo Limited. 2,414,784 Ordinary shares Note: Provide details of the circumstances giving rise to the relevant interest Part 3 – Director’s interests in contracts Detail of contract Nature of interest Name of registered holder (if issued securities) No. and class of securities to which interest relates + See chapter 19 for defined terms. Appendix 3Z Page 2 11/3/2002